Phase 1 clinical trials involving pancreatic cancer patients to evaluate the combination of a DNMTi with chemotherapy and/or PD-1/PD-L1 blockade are currently recruiting (NCT03257761, NCT01845805, NCT02959164). Here, PDCD1 is linked to familial pancreatic carcinoma.